PMID- 23499641
OWN - NLM
STAT- MEDLINE
DCOM- 20131024
LR  - 20130415
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 15
IP  - 4
DP  - 2013 Apr
TI  - Subcutaneous IgG replacement therapy is safe and well tolerated in lung 
      transplant recipients.
PG  - 752-5
LID - S1567-5769(13)00080-5 [pii]
LID - 10.1016/j.intimp.2013.02.021 [doi]
AB  - Intravenous immunoglobulin (IVIG) replacement has been shown to decrease the risk 
      of post-transplant infections secondary to hypogammaglobulinemia, however the use 
      of subcutaneous immunoglobulin (SCIG) in this population has not been reported. A 
      retrospective analysis of the efficacy and tolerability of subcutaneous 
      immunoglobulin replacement on 10 lung-transplant recipients was performed. All 10 
      patients demonstrated an increase in IgG levels at three months that was 
      sustained at 6-12 months with SCIG replacement therapy, with the majority (70%) 
      tolerating infusion without complications. The results of this study suggest that 
      subcutaneous IgG replacement therapy is a well tolerated alternative to IVIG.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Shankar, T
AU  - Shankar T
AD  - Department of Medicine, University of Pittsburgh Medical Center, USA.
FAU - Gribowicz, J
AU  - Gribowicz J
FAU - Crespo, M
AU  - Crespo M
FAU - Silveira, F P
AU  - Silveira FP
FAU - Pilewski, J
AU  - Pilewski J
FAU - Petrov, A A
AU  - Petrov AA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130315
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Hizentra)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins)
RN  - 0 (Immunologic Factors)
RN  - 0 (Vivaglobin)
SB  - IM
MH  - Aged
MH  - Electronic Health Records
MH  - Female
MH  - Humans
MH  - IgG Deficiency/blood/*prevention & control
MH  - *Immunoglobulin G/administration & dosage/adverse effects/therapeutic use
MH  - Immunoglobulins/administration & dosage/adverse effects/therapeutic use
MH  - *Immunologic Factors/administration & dosage/adverse effects/therapeutic use
MH  - Infusions, Subcutaneous
MH  - *Lung Transplantation
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
EDAT- 2013/03/19 06:00
MHDA- 2013/10/25 06:00
CRDT- 2013/03/19 06:00
PHST- 2012/09/13 00:00 [received]
PHST- 2013/02/11 00:00 [revised]
PHST- 2013/02/25 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2013/10/25 06:00 [medline]
AID - S1567-5769(13)00080-5 [pii]
AID - 10.1016/j.intimp.2013.02.021 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2013 Apr;15(4):752-5. doi: 10.1016/j.intimp.2013.02.021. 
      Epub 2013 Mar 15.